Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2009

View Archived Issues

Generics describes tegaserod salts for the treatment of irritable bowel syndrome

Eisai reports results of first quarter 2009, ended June 30

BHR to commence phase III study of progesterone in traumatic brain injury

Gefitinib prolongs progression-free survival in EGFR-positive pulmonary adenocarcinoma patients

Novel oncolytic PI3-kinase inhibitors claimed by Genentech and Roche

TpoR agonists identified by Shanghai Hengrui for the treatment of thrombocytopenia

NephroGenex completes enrollment in Pyridorin trial

FDA Advisory Committee recommends approval for Gardasil in boys and men

Anadys commences dosing in phase II ANA-598 trial in hepatitis C

Cempra initiates phase II/III trial in acute bacterial skin structure infections

FDA clears Vermillion's OVA1 test to determine risk for ovarian cancer

Pluristem Therapeutics commences enrollment in phase I PLX-PAD trial

Halozyme Therapeutics initiates phase I clinical trial with Roche biologic

Phase III aflibercept trial in metastatic pancreatic cancer discontinued

Millennium initiates phase II trial for TAK-700 in prostate cancer

Alexza reports preliminary results from phase IIb AZ-104 trial in migraine

ADX-10059 may have potential for treating levodopa-induced dyskinesia

GSK-3beta inhibitors in early development at Mitsubishi Tanabe Pharma and sanofi-aventis

Oxagen discloses CRTH2 receptor antagonists for the treatment of allergic diseases

Activity of novel antifungal FG-3622 described at ICAAC

FDA removes clinical hold on Heplisav phase III hepatitis B vaccine

S-equol efficacious in rat osteoporosis model

FDA and EMEA grant orphan drug status for trabedersen in pancreatic carcinoma

Cymbalta-treated patients with chronic low back pain maintain pain reduction

siRNA-mediated inhibition of Junin virus replication reported by Argentine scientists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...